Charles O Obonyo is an expert in Infectiology at Kenya Medical Research Institute (Kenya). Charles O Obonyo has authored 47 publications, the most recent in 2025, and is an investigator in 2 clinical trials. SLR score: 135 (community average: 125). How the SLR is computed.

LeadR Profile

Charles O Obonyo Kenya Medical Research Institute Kenya
135 ScienceLeadR Reputation 135
Network Map

Infectiology

Subspecialties: Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2025

Source: PubMed

Kenya Medical Research Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 47

Citations

Citations: 1 376 1st author: 16 Last author: 9 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Collective learning for resilience in Global South cities: a community-based systems mapping approach to integrated climate and health action.
PMID 40458106 — climate, public health, cities, learning
Front Public Health20250
Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial.
PMID 39699212 — amodiaquine, safety, mefloquine, drug therapy, drug-related side effects and adverse reactions, praziquantel, schistosomiasis, sulfalene, therapeutics, anti-bacterial agents, artesunate, antiviral agents, infections, child
Antimicrob Agents Chemother20240
Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial.
PMID 38943214 — safety, pharmaceutical preparations, ovum, drug-related side effects and adverse reactions, praziquantel, schistosomiasis, sulfalene, pyrimethamine, parasites, therapeutics, artesunate, child, drug resistance
Parasit Vectors20241
Efficacy of a Single Oral Dose of Artesunate plus Sulfalene-Pyrimethamineversus Praziquantel in the Treatment of Schistosoma mansoni in Kenyan Children: An Open-Label, Randomized, Exploratory Trial.
PMID 38460198 — tropical medicine, drug-related side effects and adverse reactions, praziquantel, sulfalene, pyrimethamine, therapeutics, artesunate, child
Am J Trop Med Hyg20244
Efficacy and safety of praziquantel plus Artemisinin-based combinations in the treatment of Kenyan children with<i>Schistosoma mansoni</i>infection: an open-label, randomized, head-to-head, non-inferiority (SCHISTOACT) trial
OpenAlex W4390837364 — safety, praziquantel, therapeutics, infections, child
medRxiv (Cold Spring Harbor Laboratory)20240

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1
Phase 4 1

By status:

Completed 2

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map